Breakthrough in the treatment of urinary tract infections
Tecuro is developing U-med, an innovative hygienic pad that prevents and treats recurrent urinary tract infections. U-med is the only medicinal alternative to antibiotics to date. The start-up is fully on track with its project schedule including a financing round that will be closed End of March.
Tecuro’s hygienic pad U-med has unqiue and patented antibacterial properties with unsurpassed skin compatibility. The pantyliner is a smart solution at crossroads between a medtech and a consumer product. Proof- of- concept on cotton has been achieved. Moreover, the start-up has now finalised U-med’s core product design for pre-clinical testing.
At the same time the team is working on a financing round. There is great interest by potential investors. To date, new potential investors have already signalled an investment interest of approximately CHF800’000. The total financing need amounts to 1.1 Mio CHF. The round will be closed by 30 March.
Next step for the company will be the development of a unique and proprietary shape of the pantyliner. Corresponding small-scale consumer tests have been initiated. Results are expected by April 2014.
About Tecuro
Tecuro was founded in 2013 and is based in Geroldswil, outside Zurich. The company is run by an experienced management team. All team members are senior experts in their respective field with top industry ties and proven track records with start-up companies. Tecuro’s patented and unique technologyuses DNA scissors to attack the bacteria cell’s nucleus and, thus, to effectively destroy the whole bacteria cells causing urinary tract infections. It is a novel mechanism of action.
0Comments
Please login or sign up to comment.
Commenting guidelines